U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H21N5O3S
Molecular Weight 447.51
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MK-3697

SMILES

COC1=CC=C(CNC(=O)C2=CC(=NC=C2C3=NC=CS3)C4=CN=CC(C)=C4)N=C1OC

InChI

InChIKey=VSOUDUXMPUHJEU-UHFFFAOYSA-N
InChI=1S/C23H21N5O3S/c1-14-8-15(11-24-10-14)19-9-17(18(13-26-19)23-25-6-7-32-23)21(29)27-12-16-4-5-20(30-2)22(28-16)31-3/h4-11,13H,12H2,1-3H3,(H,27,29)

HIDE SMILES / InChI

Molecular Formula C23H21N5O3S
Molecular Weight 447.51
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

MK-3697 a drug, currently being developed by Merck, for the treatment Insomnia. MK-3697 is a potent and selective Orexin receptor type 2 antagonist.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
MK-3697 plasma
Homo sapiens
population:
age: ADULT
sex:
food status:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.
2014 Oct 15
Patents

Sample Use Guides

Unknown
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 18:32:20 GMT 2023
Edited
by admin
on Sat Dec 16 18:32:20 GMT 2023
Record UNII
M8238285OA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MK-3697
Common Name English
(2,3'-BIPYRIDINE)-4-CARBOXAMIDE, N-((5,6-DIMETHOXY-2-PYRIDINYL)METHYL)-5'-METHYL-5-(2-THIAZOLYL)-
Systematic Name English
N-((5,6-DIMETHOXY-2-PYRIDINYL)METHYL)-5'-METHYL-5-(2-THIAZOLYL)(2,3'-BIPYRIDINE)-4-CARBOXAMIDE
Systematic Name English
Code System Code Type Description
MANUFACTURER PRODUCT INFORMATION
MK-3697
Created by admin on Sat Dec 16 18:32:20 GMT 2023 , Edited by admin on Sat Dec 16 18:32:20 GMT 2023
PRIMARY MedKoo CAT NO: 510214, CAS NO: 1224846-01-8Description: MK-3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists . MK-3697 is also the third insomnia drug, currently being developed by Merck. MK-3697 has Ki = 0.95 nM. Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. In vivo tests results on MK-3697 demonstrated improved stability and TDI profiles as well as excellent sleep efficacy across species. (Last updated: 8/6/2015).
PUBCHEM
46190695
Created by admin on Sat Dec 16 18:32:20 GMT 2023 , Edited by admin on Sat Dec 16 18:32:20 GMT 2023
PRIMARY
FDA UNII
M8238285OA
Created by admin on Sat Dec 16 18:32:20 GMT 2023 , Edited by admin on Sat Dec 16 18:32:20 GMT 2023
PRIMARY
CAS
1224846-01-8
Created by admin on Sat Dec 16 18:32:20 GMT 2023 , Edited by admin on Sat Dec 16 18:32:20 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
BINDING
Ki
TARGET -> INHIBITOR
BINDING
Ki
Related Record Type Details
ACTIVE MOIETY
Additional profiling established that compound 24 was moderately bound to plasma proteins with 84% (rat), 83% (dog), and 96% (human) binding across species and a log D of 1.9. The compound was highly permeable (Papp = 33 106 cm s1), and, while it was a substrate for P-glycoprotein (Pgp) efflux23 in mouse and rat with efflux ratios of 5.7 and 4.9, the compound demonstrated less Pgp susceptibility in human with a ratio of 2.9. Compound 24 was not a potent reversible inhibitor of CYP3A4, CYP2C9, or CYP2D6 (IC50s = 17, >50, >50 .MU.M), and it was not a potent activator of PXR with an EC50 of greater than 30 .MU.M and 16% activation compared to rifampicin control at 30 .MU.M. Off-target profiling of 2-SORA 24 showed no activities less than 10 .MU.M in a panel of 165 assays encompassing a range of targets including GPCRs, enzymes, and ion channels. Pharmacokinetic profiling of 2-SORA 24 revealed the compound had moderate clearance in rat and low clearance in dog with half-lives in an acceptable range for once-nightly treatment of insomnia. These data supported the selection of compound 24 as a preclinical candidate subsequently known as MK-3697.